Penumbra, Inc.

As of October 17, 2025, Penumbra, Inc. is considered expensive and overvalued with a P/E ratio of 84 and an EV to EBITDA of 69.41, despite a 23.11% stock return over the past year, which outperformed the S&P 500's 14.08% return but lags behind its longer-term performance.

As of October 17, 2025, Penumbra, Inc. is considered overvalued with high valuation ratios, including a P/E of 84, compared to peers like Hologic and The Cooper Companies, and its stock price has shown significant volatility between a 52-week high of 310.00 and a low of 199.01.

As of October 17, 2025, Penumbra, Inc. is considered overvalued with high valuation ratios despite a recent 1-year return of 23.11%, underperforming the S&P 500 over the long term with a 5-year return of only 16.36%.

As of October 10, 2025, Penumbra, Inc. is considered very expensive and overvalued with a high P/E ratio of 84, a Price to Book Value of 8.27, and an EV to EBITDA of 69.41, significantly exceeding industry averages and its peers, despite a strong return of 35.26% over the past year, which is below the S&P 500's 13.36%.

As of October 3, 2025, Penumbra, Inc. is considered very expensive due to high valuation ratios, including a P/E of 84, despite a recent 31.32% return over the past year, which lags behind the S&P 500's five-year return of 100.56%.

As of September 4, 2025, Penumbra, Inc. shows a mildly bullish technical trend, supported by bullish MACD and KST indicators, despite some bearish signals in daily moving averages and mixed performance compared to the S&P 500.

As of August 15, 2025, Penumbra, Inc. is considered very expensive due to its high valuation metrics, including a P/E ratio of 84 and an EV to EBITDA of 69.41, which significantly exceed industry averages, while its stock performance has lagged behind the S&P 500 over the long term.

Penumbra, Inc. reported impressive financial results for the quarter ending June 2025, with record net sales of USD 339.45 million and a net profit of USD 45.27 million. The company achieved a significant operating cash flow of USD 201.5 million and reduced raw material costs by 23.62%, while maintaining a debt-free status.

As of April 24, 2025, Penumbra, Inc. is considered overvalued with a P/E ratio of 84, significantly higher than its peers, and its financial metrics do not justify this premium, as evidenced by lower returns and recent stock performance lagging behind the S&P 500.

As of May 14, 2025, Penumbra, Inc. shows a mildly bullish trend due to positive daily moving averages, despite mixed signals from weekly and monthly indicators.

As of March 2022, the management team of Penumbra, Inc. includes Chairman and CEO Adam Elsesser, Chief Innovator Dr. Arani Bose, and several Independent Directors: Harpreet Grewal, Don Kassing, Janet Leeds, Bridget O'Rourke, and Surbhi Sarna. They are responsible for the company's strategic direction and operations.

Penumbra, Inc. is a healthcare company specializing in interventional therapies for neuro and peripheral vascular conditions, with recent net sales of $324 million and a market cap of approximately $9.91 billion. Key financial metrics include a P/E ratio of 84.00 and a return on equity of 9.83%.

As of Jun 18, Penumbra, Inc. has a market capitalization of $9.91 billion, with recent net sales of $1.24 billion and a net profit of $42.23 million. The company reported shareholder's funds of $1.15 billion and total assets of $1.53 billion as of Dec 24.